Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | PYGL | P06737 | 9/20 | 0.44 |
| ▸ | PYGM | P11217 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NHERF1 | O14745 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14845704 | 0.86 | TP53 (0.54) | KDM4ENPC1RAB9AMAPTEGFR | |
| SCHEMBL19085805 | 0.84 | EGFR (0.44) | KDM4ENPC1RAB9AMAPTEGFR | |
| SCHEMBL12827225 | 0.82 | KDM4E (0.64) | KDM4EKMT2AMEN1NPC1RAB9A | |
| SCHEMBL12826973 | 0.80 | KDM4E (0.64) | KDM4EKMT2AMEN1NPC1RAB9A | |
| SCHEMBL12846301 | 0.78 | KDM4E (0.69) | KDM4EKMT2AMEN1NPC1RAB9A | |
| SCHEMBL13222833 | 0.78 | CA12 (0.41) | KDM4ENPC1RAB9AMAPTEGFR | |
| SCHEMBL17149665 | 0.76 | ADRB2 (0.58) | KDM4EKMT2AMEN1NPC1RAB9A | |
| SCHEMBL15099964 | 0.76 | KDM4E (0.79) | KDM4EKMT2AMEN1NPC1RAB9A | |
| SCHEMBL13204716 | 0.74 | MAPT (0.57) | KDM4EKMT2AMEN1NPC1RAB9A | |
| SCHEMBL6517075 | 0.74 | KDM4E (0.63) | KDM4EKMT2AMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952049-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-02-10 | — | — | US | disclosed |
| US-20130178471-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vextex Pharmaceuticals Incorporated (US) | 2013-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178471-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | KDM4E 4235/4885KMT2A 4313/4885MEN1 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.